BARCELONA, Spain — Health-related quality of life (HRQoL) is not further compromised by the addition of nivolumab (Opdivo) immunotherapy to first-line cisplatin-based chemotherapy in patients with […]

BARCELONA, Spain — Long-awaited overall survival data from the KEYNOTE-522 trial has lifted spirits in the triple-negative breast cancer (TNBC) community.  The trial confirmed the survival […]

In late August, a federal judge ruled that a Medicare policy, which essentially prohibits oncology practices from delivering medications to patients at home, can stand. Some experts […]

BARCELONA, Spain — Oncologists struggle to discuss fertility and sexual health with patients, and the tools available to qualitatively and quantitatively assess these aspects are limited. […]

Organ preservation may be a viable option for select patients with locally advanced rectal cancer, according to the first results of the NO-CUT trial. The study […]

BARCELONA, Spain — A higher disease-free survival (DFS) rate was seen for patients with stage II/III colon cancer given adjuvant aspirin than for those given placebo […]

The initial results of the IMbrave050 trial raised hopes that an effective adjuvant regimen for hepatocellular carcinoma (HCC) might finally have arrived.  Patients with HCC treated […]

BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer significantly improved survival, reducing the risk for death by 25%, according […]

BARCELONA, Spain — Breastfeeding is possible even after breast cancer, according to findings from two international studies led by Italian researchers, presented at the European Society […]